Pushing the boundaries of science to discover, develop and deliver life-changing medicinesWe make medicines that address serious medical conditions across multiple therapeutic areas. Our nine FDA-approved medicines are only the beginning of our quest to solve the human body's most complex mysteries and positively impact lives.
Regeneron-Invented FDA-Approved Medicines
advancing our medicines in 2021:
key regulatory updates
In 2021, our medicines reached more people than ever through expanded indications and new regulatory approvals. These regulatory milestones occurred between January 2021 and April 2022.
Investigational indications not yet approved by health authorities or regulatory agencies.
European Commission (EC) Approved by the FDA and EC for first-line treatment of advanced non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression as a monotherapy Approved by the FDA and EC for advanced basal cell carcinoma (BCC)
Known as Ronapreve outside the U.S.
European Commission (EC) Approved by the FDA and EC for homozygous familial hypercholesterolemia (HoFH) Established license and collaboration agreement with Ultragenyx Pharmaceutical Inc. to clinically develop, commercialize and distribute outside of U.S.